Resource Summary Report

Generated by RRID on Sep 6, 2026

Mouse monoclonal anti-CD163

RRID:AB_2756375
Type: Antibody

Proper Citation

Leica Biosystems Cat# NCL-L-CD163, RRID:AB_2756375

Antibody Information

URL: http://antibodyregistry.org/AB_2756375

Proper Citation: Leica Biosystems Cat# NCL-L-CD163, RRID:AB_2756375

Target Antigen: CD163

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: IHC

Antibody Name: Mouse monoclonal anti-CD163

Description: This monoclonal targets CD163

Target Organism: human

Clone ID: 10D6

Antibody ID: AB_2756375

Vendor: Leica Biosystems

Catalog Number: NCL-L-CD163

Record Creation Time: 20231110T033316+0000

Record Last Update: 20260829T002202+0000

Ratings and Alerts

No rating or validation information has been found for Mouse monoclonal anti-CD163.

No alerts have been found for Mouse monoclonal anti-CD163.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 22 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Bernstein AJ, et al. (2026) Compartment-specific tumor-infiltrating immune cells and prognosis in breast cancer. iScience, 29(2), 114759.

Pham FK, et al. (2026) Melanoma cell states shape spatial tumor-immune ecosystems to dictate the efficacy of anti-PD1 immunotherapy. Journal for immunotherapy of cancer, 14(6).

Solomon BJ, et al. (2025) The Impact of the Tumor Microenvironment on the Effect of IL-1 ? Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials. Cancer research communications, 5(4), 632.

Suzuki H, et al. (2025) GALNT7 Stratifies dMMR/MSI Colorectal Cancer into Distinct Molecular Subsets Associated with Prognosis and PD-L1 Expression. Cancer research communications, 5(9), 1530.

Fiore D, et al. (2025) A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities. Cell reports. Medicine, 6(4), 102029.

Wu SG, et al. (2025) Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis. Clinical and translational medicine, 15(1), e70149.

Trotta R, et al. (2025) Activated T Cells Break Tumor Immunosuppression by Macrophage Reeducation. Cancer discovery, 15(7), 1410.

Marzano P, et al. (2025) Tissue-Specific Immunosuppressive and Proliferating Macrophages Fuel Early Metastatic Progression of Human Colorectal Cancer to the Liver. Cancer immunology research, 13(11), 1783.

Sahl RE, et al. (2024) Prolonged Endurance Exercise Increases Macrophage Content and Mitochondrial Respiration in Adipose Tissue in Trained Men. The Journal of clinical endocrinology and metabolism, 109(2), e799.

Koganemaru S, et al. (2024) The tumor immune microenvironment and therapeutic efficacy of trastuzumab deruxtecan in gastric cancer. Cancer research communications.

Roemer MGM, et al. (2023) Multi-scale spatial modeling of immune cell distributions enables survival prediction in primary central nervous system lymphoma. iScience, 26(8), 107331.

Liu X, et al. (2023) Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity. Cancer cell, 41(6), 1073.

Biermann J, et al. (2022) Dissecting the treatment-naive ecosystem of human melanoma brain metastasis. Cell, 185(14), 2591.

Wang LB, et al. (2021) Proteogenomic and metabolomic characterization of human glioblastoma. Cancer cell, 39(4), 509.

Dupont M, et al. (2020) Tuberculosis-associated IFN-I induces Siglec-1 on tunneling nanotubes and favors HIV-1 spread in macrophages. eLife, 9.

Roy A, et al. (2020) Hippocampal granule cell dispersion: a non-specific finding in pediatric patients with no history of seizures. Acta neuropathologica communications, 8(1), 54.

Krug K, et al. (2020) Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell, 183(5), 1436.

Toulmonde M, et al. (2020) High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies. EBioMedicine, 62, 103131.

Gillette MA, et al. (2020) Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. Cell, 182(1), 200.

Halbrook CJ, et al. (2019) Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. Cell metabolism, 29(6), 1390.